CSIMarket Company Name, Ticker, Suppliers, else..
 
Aclaris Therapeutics Inc   (NASDAQ: ACRS)
 
Price: $6.0500 $0.04 0.666%
Day's High: $6.059999942779541 Week Perf: -7.42 %
Day's Low: $ 5.84 30 Day Perf: 16.35 %
Volume (M): 1,632,040 52 Wk High: $ 6.60
Volume (M$): $ 0 52 Wk Avg: $3.72
Open: $5.97 52 Wk Low: $1.74



 Market Capitalization (Millions $) 779
 Shares Outstanding (Millions) 129
 Employees 73
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -70
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aclaris Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address unmet needs in dermatology and immunology. The company has a diverse pipeline of drug candidates targeting various skin and hair disorders, including alopecia areata, vitiligo, and common warts. Aclaris Therapeutics aims to provide effective and safe treatment options for patients suffering from these medical conditions. The company's research and development efforts are centered on discovering novel compounds and utilizing advanced technologies to improve patient outcomes.


   Company Address: 701 Lee Road, Suite 103 Wayne 19087 PA
   Company Phone Number: 324-7933   Stock Exchange / Ticker: NASDAQ ACRS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.06%    
BMY   -0.7%    
JNJ   -2.63%    
LLY   -7.23%    
MRK   -1.92%    
TEVA   -2.38%    
• View Complete Report
   



Shares

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Published Mon, Jan 6 2025 9:30 PM UTC

Aclaris Therapeutics: Strategic Inducement Grants Amid Promising Clinical AdvancesOn September 17, 2024, Aclaris Therapeutics Inc. announced the initiation of dual Phase 2a clinical trials for ATI-2138, aiming to address the critical dermatological condition of atopic dermatitis and the gastrointestinal ailment of ulcerative colitis. This significant move signaled the compan...
Clinical Study

Aclaris Therapeutics Launches Dual Phase 2a Trials for ATI-2138, Targeting Atopic Dermatitis and Ulcerative Col...

Published Tue, Sep 17 2024 11:00 AM UTC

Aclaris Therapeutics has recently completed a pivotal step in the journey of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, by dosing the first patient in not one, but two Phase 2a clinical trials. These trials aim to evaluate the efficacy of ATI-2138 in treating moderate to severe atopic dermatitis and moderate to severe ulcerative colitis, respectively. The...
Management Changes

Aclaris Therapeutics: Charting a Path to Financial Reinvention and Leadership Reinforcement

Published Tue, Jan 16 2024 12:01 PM UTC



Aclaris Therapeutics, a prominent player in the healthcare sector, has recently announced significant leadership changes and a strategic business review. The decision comes after a period of financial underperformance, with the company s year-to-date stock performance showing a decline of 12%. Additionally, Aclaris Therapeutics reported a net loss of $115 million f...
Clinical Study

JAK Inhibitor ATI-1777: A Promising New Development in Atopic Dermatitis Treatment.

Published Wed, Jan 10 2024 12:00 PM UTC

: Aclaris Therapeutics recently announced positive top-line results from their four-week Phase 2b trial of ATI-1777, an investigational topical soft Janus kinase (JAK) inhibitor, in patients with mild to severe atopic dermatitis (AD), with the drug having achieved a statistically significant result in the primary efficacy endpoint at week four. Atopic Dermatitis (AD), a pre...
Licensing Agreement

Aclaris Therapeutics Teams Up with Sun Pharma in a Game-Changing Patent License Agreement for Alopecia Treatment.

Published Tue, Dec 5 2023 9:01 PM UTC

Aclaris Therapeutics Partners with Sun Pharma in Patent License Agreement for AlopeciaIn a significant move towards revolutionizing treatment options for alopecia, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a leading clinical-stage biopharmaceutical company, announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma) on December 5, 2...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 93.14
Price to Sales (Expected) -
Price to Book 5.43
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.85
Working Capital Ratio 4.03
Leverage Ratio (MRQ) 0.38
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.56 $
Revenues (TTM) 0.06 $
Cash Flow (TTM) -
Cash 0.82 $
Book Value 1.12 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 114,616
Net Income per Employee (TTM) -954,274
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.05

Profitability Ratios Current
Gross Margin (MRQ) 80.21 %
Operating Margin (MRQ) -1111.82 %
Net Margin (MRQ) -993.19 %
Net Cash Flow Margin (MRQ) 435.87 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Aclaris Therapeutics Inc's Segments
Single reportable segment    100 % of total Revenue
Contract Research Single reportable segment    26.9 % of total Revenue
Licensing revenue Single reportable segment    73.1 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.